Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular Malformation and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KRIT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KRIT1 Recombinant Protein (Full-Length / FERM Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View KRIT1 Products |
| Gene Delivery | KRIT1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and rescue assays. |
View KRIT1 Products |
| Benchmark Ab | Anti-KRIT1 Recombinant Antibody Recombinant positive control for assay validation. |
View KRIT1 Products |
| Validator | KRIT1 siRNA Set For knockdown verification and disease modeling. |
View KRIT1 Products |
| Related Target A | RAP1A Direct binding partner of KRIT1; critical for cellular junction stabilization. |
View RAP1A Products |
| Related Target B | ROCK2 Downstream kinase pathway; hyperactivated upon KRIT1 loss-of-function. |
View ROCK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular scaffold stability and folding | Optimized expression systems with strict sequence verification and theoretical MW quality control. |
| Protein-Protein Interaction (PPI) screening | High-purity functional domains (FERM, NPXY) available for robust binding assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and validated siRNA sets included |
| False Positives | Sequence-verified wild-type and truncated control proteins |
Live KRIT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development targeting KRIT1 (CCM1) is expanding beyond traditional symptom management toward disease-modifying interventions. As an intracellular scaffold protein regulating endothelial cell-cell junctions, loss-of-function mutations in KRIT1 lead to Cerebral Cavernous Malformations (CCM). The current drug discovery landscape is focused on restoring endothelial barrier function, utilizing small molecule stabilizers, gene therapies, and downstream signaling inhibitors (such as ROCK inhibitors) to bypass or correct KRIT1 deficiency.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Stabilizers | Recursion Pharmaceuticals, Academic Spin-offs | Cerebral Cavernous Malformations (CCM) | PPI binding assays (Need high-purity KRIT1 and RAP1A proteins) |
| Gene Therapy (AAV/Lentivirus) | Preclinical Biotechs | CCM1-deficient Vascular Diseases | Rescue assays in cell lines (Need sequence-verified Lentivirus) |
| Downstream Kinase Inhibitors | Biopharma clinical pipelines | Vascular Hyperpermeability, Stroke | Pathway readout validation (Need KRIT1 siRNA for disease modeling) |